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LIST OF ABBREVIATIONS 
 
AGE   advanced glycation endproduct  
BMI   body mass index  
CIMT carotis intima media thickness 
FN3K   fructosamine-3-kinase 
GCK   glucokinase 
GCKR   glucokinase regulatory protein  
GFR   glomerular filtration rate 
HDL   high density lipoprotein  
LDH   lactate-dehydrogenase 
LDL   low density lipoprotein  
MDRD  Modification Diet in Renal Deseases 
NEG   non-enzymatic glycation 
PCR   polimerase chain reaction 
RFLP   restriction fragment length polymorphism 
SNP   single nucleotide polymorphism  
T2DM   type 2 diabetes mellitus 
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1. INTRODUCTION  
 
Accelerated population ageing and urbanization, growing prevalence of obesity 
dramatically increased the incedence of type 2 diabetes mellitus (T2DM).   
In the year 2000, 170 million people suffered in T2DM worldwide, and according the 
latest estimations, this is expected to double by the year 2030, reaching the number of 360 
million patients. Diabetic micro- and macrovascular complications are significant economic 
burden to health care systems, therefore diabetes management should focus on preventing or 
delaying the onset of these complications. 
Diabetic nephropathy is one of most dreaded microvasular complication of diabetes 
mellitus, subjects with diabetic nephropathy have four-fold higher cardiovasular risk 
compared with subjects without diabetic nephropathy.  
Bad glycemic control, oxidative stress and the formation of advanced glycation 
endproducts (AGE) have a pivotal role in the pathogenesis. Among many others, genetic 
susceptibility is one of the most relevant risk factor. The genetic background of T2DM is 
complex and details yet remained unclarified. Several genes are involved in the pathogenesis, 
the genetic susceptibility can be determined as interac ion of each diabetes genes, 
substantially influenced by the environmental factors and ethnicity. 
Non-enzymatic glycation, is a process in which sugars react spontaneously with side 
chains of intra- and extracellular proteins ultimately leading through a series of further 
reactions to the formation of AGEs, which have crucial role in the development of diabetic 
microvascular complications. 
AGEs are accumulated in tissues by ’in situ’ formation or via circulation. Incomplete 
detoxification of AGEs by the monocyte/macrophage system produces still toxic, low-
molecular weight fragments, which can be eliminated only through the kidneys. During the 
elimination, AGE fragments bind to specific AGE receptors of the proximal tubular epithel 
cells and trigger inflammation ultimately leading to renal damage and the onset of 
albuminuria (diabetic nephropathy). In severe cases, proteinuria can reach the nephrotic 
range, which can cause ’per se’ renal damage. Therefor  a vicious circle might develop.  
There are several hypothesis as to how proteinuria, renal damage and atherosclerosis 
might be in strong association. Some say that proteinuria is a marker of renal damage and 
endothel dysfunction, in others oppinion proteinuria is not only a ’marker’, but the ’maker’ as 
well. 
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Filtrated protein is reabsorbed by the proximal tubular cells.In heavy proteinuria 
tubular cells get exhausted and damaged,cytokines iduce inflammation resulting in 
tubulointerstitial fibrosis and ultimately end stage renal disease. 
Serum total lactate-dehydrogenase (LDH) activityis a commonly used 
laboratoryparameter in the daily clinicalroutine. When cells are injured the enzyme is released 
into the bloodstream. Measuring the enzyme activity and the determination of isoenzyme 
pattern is highly informative in several diseases. However, there isn’t any clinical laboratory 
test to clarify the etiology of nephrotic syndrome or to predict the prognosis. 
Non-enzymatic glycation has been considered irreversible until a new intracellular 
enzymatic deglycation mechanism was discovered. A recently identified enzyme, namely the 
fructoseamine-3-kinase (FN3K) is considered as a potential protein repair enzyme, 
responsible for deglycation of intracellular proteins.It is able to phosphorylate low molecular 
mass fructosamines (i.e. fructoselysine) and other protein-bound fructosamines on the third 
carbon, resulting in an unstable compound, which then decomposes spontaneously to 
inorganic phosphate, to 3-deoxyglucasone and to the unmodified protein. The FN3K gene is 
located on chromosome 17q25, composed of 6 exons and encodes 309 amino acids. This 35 
kDa monomeric enzyme is expressed constitutively in all tissues, however higher expression 
is observed in tissues exposed to extreme glycation, such as peripheral and central nervous 
system, kidneys, heart and in human erythrocytes. The role of FN3K was also verified in 
animal model, FN3K -/- mice have 2.5 fold higher level of intracellular glycated protein than 
in control mice. 
Glucokinase (GCK) is a predominant glucose phosphorylating enzyme expressed in 
the liver and in the beta-cells of the Langerhans islets, playing a pivotal role in the glucose-
stimulated insulin release as a physiological glucose-sensor. Pancreatic islets and the liver 
contain a regulatory protein (glucokinase regulatory protein, GCKR), which inhibits GCK in 
an allosteric manner with respect to glucose concentration byforming an inactive heterodimer. 
The inhibitory effect of GCKR is enhanced by fructose-6-phosphate and antagonized by 
fructose-1-phosphate. The 27 kb GCKR gene is located on chromosome 2p23 containing 19 
exons and encodes a 68 kDa protein. 
Genomewide association studies showed, that common functional variants of the 
GCKR gene are associated with fasting plasma glucose and serum triglycerides. More 
recently, both functional variants of the GCKR gene w re widely investigated as candidate 
T2DM susceptibility variants, and susceptibility genes for hypertigliceridemia. 
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Hypertriglyceridemia confers an independent significant risk for cardiovascular 
diseases, accordingly studying the possible associati n of rs780094 and rs1260326 of the 
GCKR gene on metabolic risk traits might have importance in cardiovascular diseases. 
Taking all this together; association studies of SNPs influencing the lipid traits and the 
AGE level have a capital importance in the risk asses ment of diabetic (diabetic nephropathy) 
and non-diabetic kidney diseases. 
  
 6 
2. AIMS OF THE STUDY 
 
1. Determination the allelic distribution and association study of the SNP G900C 
(rs1056534) of the FN3K gene in T2DM patients and in healthy control subjects. 
Study the possible protective nature against diabetic microvascular complications 
particularly against diabetic nephropathy. 
 
2. Determination the allelic distribution and association study of the functional 
variants of the GCKR gene (rs780094, rs1260326) on carbohydrate and lipid 
metabolism and the carotid intima-media thickness (CIMT) in T2DM patients, in 
metabolic syndrome patients and in healthy control subjects. Study the possible 
susceptibility or protective nature against diabetic microvascular complications 
particularly against diabetic nephropathy. 
 
3. Study the LDH activity and LDH isoenzyme pattern and the prognostic value of 
LDH in nephrotic syndrome and in non-nephrotic syndrome patients. 
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3. MATERIALS AND METHODS 
 
3. 1. Study population 
 
All patients were enrolled from the 2nd Department of Medicine and Nephrological Center, 
University of Pécs, Hungary.T2DM was diagnosed according to the criteria of the World 
Health Organization. Metabolic syndrome was diagnosed according to modified criteria of the 
Adult Treatment Panel III of National Cholesterol Education Program. 
Controls were gathered from trauma units, blood donors, medical staff and university 
students, they were free from any single clinical or aboratory sign of T2DM or metabolic 
syndrome; their medical history were also free from any systemic or organ-specific disease. 
All participants gave their informed consent and the study was approved by the local Ethics 
Committee. 
 
3. 2. Biochemical and clinical data 
 
All participants underwent a detailed medical examination. Laboratory parameters were 
assessed using routine methods from fasting blood samples. BMI was calculated as weight 
(kg) divided by height (m2). Glomerular filtration rate (GFR) was estimated by the 
Modification Diet in Renal Deseases (MDRD) formula. CIMT was measured by B-mode 
ultrasound device with a high resolution 10 MHz linear transducer. LDH isozymes were 
separated by agarose gel electrophoresis and the proportions of the enzymes were determined 
by their activity with densitometry. 
 
3. 3. Genotyping 
 
DNA samples and the clinical data were deposited into the Central Biobank governed by the 
University of Pécs, as part of the National Biobank Network of Hungary, approved by the 
national Scientific Research Ethics Committee. Genotyping was carried out at the Department 
of Medical Genetics, Faculty of Medicine, University of Pécs. 
DNA was isolated from peripheral blood leukocytes by standard salting out method. 
Genotyping was determined with polymerase chain reaction/restriction fragment length 
polymorphism (PCR-RFLP) method. 
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The FN3K G900C polymorphism site was amplified using the primers 5’- GGT TTC 
CCC AGA TCC TTC TTC (forward) and 5’- GAC AGG GGG ATT GGT ATG TG 
(reverse).The 400 bp amplicon was digested with Eco130I (StyI) restriction enzyme; after 
digestion 139, 261 bp fragments were in the samples with GG genotype, in homozygous CC 
samples 43, 96, 261 bp products were detected. For amplification PTC 200 PCR equipments 
were used, the conditions were similar for all polymorphisms: a 2 min initial denaturation at 
96 oC was followed by 35 cycles of 20 sec at 96 oC; 20 sec at 60 oC; and 20 sec at 72 oC; the 
final extension occurred at 72 oC for 5 min. The amplification was carried out in a final 
volume of 50 µl containing 5 µl reaction buffer (500 mM KCl, 14 mM MgCl2, 10 mM Tris-
HCl, pH 9.0), 1 µl 50 mM MgCl2, 0.2 mM of each dNTP, 1 U of Taq polymerase, 0.2 mM of 
the adequate specific primer pairs and 1 µg DNA. 
 By GCKR gene polymorphism, for PCR amplification, the following primers were 
used: GCKR rs1260326: forward 5’-TGC AGA CTA TAG TGG AGC CG-3’ and reverse 5’-
CAT CAC ATG GCC ACT GCT TT-3’; GCKR rs780094: forward 5’-GAT TGT CTC AGG 
CAA ACC TGG TAG-3’ and reverse 5’-CTA GGA GTG GTG GCA TAC ACC TG-3’. An 
MJ Research PTC-200 thermal cycler was used for the amplification. PCR conditions were 
the following: predenaturation at 96°C for 2 min; followed by 35 cycles of denaturation at 
96°C for 20 sec (rs1260326), 30 cycles of denaturation at 96°C for 20 sec (rs780094); 
annealing at 60°C for 20 sec (rs1260326), and at 62°C for 30 sec (rs780094); primer 
extension for 30 sec at 72°C; and final extension at 72°C for 5 min. The amplicons were 
digested by HpaII restriction endonuclease (rs12603) and PscI (rs780094). The digestion of 
231 bp amplicon of rs1260326 CC genotype resulted in 18, 63, 150 bp fragments; the TT 
genotype 18 and 213 bp; while the heterozygous genotype 18, 63, 150, 213 bp fragments. For 
the rs780094 427 bp amplicon the following fragments were detected: GG genotype 62, 177, 
188 bp; AA genotype 62, 365 bp; heterozygous genotype 62, 177, 188, 365 bp fragments. 
 
3. 4. Statistical analysis 
 
All statistical procedures were performed using the SPSS 15.0 software. P values ≤ 0.05 were 
considered statistically significant. Kolmogorov-Smirnov test was used to assess sample 
distribution. Clinical and biochemical characteristic  of the study participants were compared 
with one-way ANOVA, with analysis of covariance (ANCOVA) and with Kruskal-Wallis 
followed by Mann-Whitney U test. To test for correlation, we used the Pearson’s and the the 
Spearman’s rho test, according to the distribution. A stepwise linear regression was carried 
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out to determine the independent predictors. Survival curves were calculated using Kaplan-
Meier method and the curves were compared by log-rank test.Chi-square test was used to 
compare the qualitative data. Multivariate logistic regression analysis models were used to 
risk evaluation. 
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4. RESULTS AND DISCUSSION  
 
4. 1. Studying the fructosamine-3-kinase G900C polymorphism 
 
Recent studies revealed an enzyme, called FN3K, which can protect proteins against NEG. 
Several SNPs of the FN3K gene were identified, among which the CC allelic variant of the 
G900C SNP was associated inversely with the enzyme activity. In this study we investigated 
the possible association between clinical parameters and the presence of late diabetic 
complication and the G900C polymorphism of FN3K genein type 2 diabetic subjects. 
The genotype frequencies were as follows, GG: 41%, GC: 54%, CC: 5% in subjects with 
T2DM and GG: 43%, GC: 51%, CC: 6% in the controls, and followed the Hardy-Weinberg 
equilibrium. We did not observe significant differenc s in the genotype frequencies between  
the groups. 
Several reports suggested the potencial association between FN3K activity and the glycated 
haemoglobin level, however, they failed to detect correlation between SNPs of FN3K and the 
HbA1c levels. On the contrary, we found significantly decreased HbA1c levels in T2DM 
subjects with the CC genotype compared with CG and GG variants (CC: 6.48±0.05%; GC: 
7.66±0.09%; GG: 7.68±0.09%, p<0.001). Subjects with the highest HbA1c level (3. tertile) 
had significantly lower frequency of the C allele compared with subjects with the lowest 
HbA1c levels (1. tertile) (1. tertile: 34.3% vs. 3. tertil : 29.0, p<0.05). 
Furthermore, we found association between the polymrphism and the onset of disease, in 
case of the CC allelic variant T2DM was diagnosed at a later age than in case of GC or GG 
variants (p<0.05). 
Some studies reported association between FN3K activity and the diabetic microvscular 
complications. According the latest observations, i diabetic nephropathy the level of FN3K 
mRNA was significantly lower in the progressors compared with the non-progressors, 
suggesting the prognostic effect of the enzyme. 
Logistic regression analysis revealed that the CC variant was not associated with the diabetic 
microvascular complications (diabetic nephropathy, neuropathy and retinopathy), adjusted for 
age, gender, BMI, duration and onset of diabetes (OR=1.036, CI 95% 0.652-1.647, p=0.880; 
OR=0.985, CI 95% 0.564-1.721 p=0.958; OR=1.213, CI 95% 0.470-3.132, p=0.690, 
respectively). 
The analyzed SNP does not induce amino acid change; moreover it is present neither in 
sequences of splicing sites nor in binding sites of transcription factors, so the altering effect 
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on enzyme activity of the SNP is not fully elucidated. It might presumably be due to sequence 
variations in or near the FN3K gene, or due to the linkage disequilibrium with the A-385G 
polymorphism of the promoter region of the FN3K gene, or with other regulatory elements; 
however other mechanisms cannot be ruled out. 
 
4. 2. Studying the GCKR functional gene variants 
 
Recently, GCKR gene were widely investigated as candidate T2DM susceptibility gene. 
Genomewide association studies showed, that common functional variants of the GCKR gene 
(rs1260326, rs780094) are associated with triglycerides. Other studies revealed association 
with the fasting plasma glucose, insulin levels. Inverse effect on triglycerides and fasting 
plasma glucose concentration was also confirmed in different populations. In SNP rs1260326 
of the GCKR a C/T change results in a proline to leucine substitution in the aminoacid 
sequence of the encoded protein. This change is very likely to modify the structure of the 
protein and if this structural alteration is in the binding site of fructose-6-phosphate or 
fructose-1-phosphate it can influence the function of the protein. GCKR rs1260326 variant 
(P446L) is in strong linkage disequilibrium (r2 = 0.96) with rs780094 variant. 
In this study, we investigated the functional variants of the GCKR gene (rs780094, 
rs1260326) in T2DM patients, in metabolic syndrome patients and in healthy control subjects. 
In the current study, we could replicate the previously reported positive associations of the 
two functional variants of GCKR gene (rs780094 and rs1260326) and triglyceride/glucose 
metabolism in the Hungarian population; our results confirmed the inverse association with 
serum triglycerides and plasma glucose levels in T2DM and metabolic syndrome patients. 
The genotype profiles including the minor allele frquencies were similar in the study groups 
(rs780094: A allele, controls: 47.4%, T2DM: 46.9%, metabolic syndrome: 47.6%, p>0.05; 
rs1260326: T allele, controls: 48.8%, T2DM: 47.1%, metabolic syndrome: 46.8%, p>0.05). 
All genotypes were in Hardy-Weinberg equilibrium.  
Body mass index, fasting plasma glucose, lipid profile and CIMT in subjects with metabolic 
syndrome, T2DM and controls by individual genotypes are presented in table A and B. 
BMI is not associated either with rs780094 or with rs1260326, however plasma glucose levels 
were associated with both variants significantly (p<0.05). We observed association of the 
minor allele of rs780094 and rs1260326 with elevated s rum triglycerides in all groups. We 
found no relationship between variants of GCKR gene a d total serum cholesterol levels, 
however HDL-cholesterol level was significantly lower in subjects homozygous for the minor 
 12 
allele for both rs780094 and rs1260326, but only in T2DM patients, moreover LDL-
cholesterol was significantly elevated in homozygous patients, but only in the metabolic 
syndrome group. We also correlated the CIMT, the subclinic marker of atheroslerosis in 
patients with T2DM and metabolic syndrome. Both variant was associated with increased 
CIMT. 
Subjects with the highest glucose level(3. tertile) had significantly lower frequency of the 
minor A and T allele compared with subjects with the lowest glucose level (1. tertile) and 
similarly subjects with the highest triglycerides(3. tertile)had significantly higher frequency of 
the minor A and T allele compared with subjects with the lowest triglycerides(p<0.05). 
Regression analysis revealed that both rs780094 and rs1260326 confer a significant 
susceptibility for the development of hypertriglycerid mia; after adjusting the results for age, 
gender, total serum cholesterol, the presence of coronary artery disease and statin therapy 
(rs780094, OR (CI 95%):1.748(1.256-2.435), p=0.001; rs1260326, OR (CI 95%): 
1.311(1.078-1.596), p=0.007). 
None of the variants were associated with the development of T2DM and metabolic syndrome 
or with the diabetic microvascular complications (diabetic nephropathy, neuropathy and 
retinopathy) by logistic regression analysis. 
GCKR plays an important role in the carbohydrate and lipid metabolism. There are some 
hypotheses for the mechanism of action, however its physiological role has not been clarified 
yet. 
 
4. 3. 3. Study the LDH activity and LDH isoenzyme pattern and the prognostic value of 
LDH in nephrotic syndrome and in non-nephrotic syndrome patients. 
 
Measuring the serum total LDH activity is an important diagnostic parameter in different 
diseases with tissue-damage because during cell-lesion this enzyme is released into the 
circulation [8]. Determination of LDH isozyme pattern is a great assistance in elucidating the 
origin of the enzyme. The role of serum total LDH activity in different kidney diseases has 
been studied only in few studies so far. 
In nephrotic syndrome the filtrated proteins overflow the proximal tubules where tubular cells 
reabsorb proteins by endocytosis. Since this is a high energy-demanding procedure, tubular 
cells may get exhausted and damaged soon. Large quantities of proteins have a toxic effect on 
tubular cells by increasing the cell proliferation a d apoptosis thus the tubular cell turnover 
accelerates. Glomerular barrier protects normally serum proteins from filtration into the urine. 
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Presumably, in nephrotic syndrome some serum proteins (e.g. albumin and transferrin) get 
into the proximal tubules and induce inflammation resulting in damage of apical and 
basolateral membrane of the epithelial cells, therefore LDH can freely flow out from the 
cytoplasm into the serum and urine. 
We studyed the LDH activity and LDH isoenzyme pattern and the prognostic value of LDH in 
nephrotic syndrome (NEPHR) and in non-nephrotic syndrome patients (NON-NEPHR) and in 
hypoalbuminemic subjects with different gastrointestinal diseases as a positive control group 
(KONTR). 
Serum total LDH activity of the NEPHR group was significantly higher compared with the 
NON-NEPHR and KONTR groups (p<0.001). LDH isoenzyme patterns were determined in 
three randomly selected subgroups. 
Both the activity and the ratio of kidney specific LDH-2 were significantly higher in the 
nephrotic subgroup compared with the non-nephrotic and control subgroups (p<0.001). 
The elevation of serum total LDH activity in nephrotic patients is not a marker of 
retention.We investigated the serum total LDH activity (prior to dialysis) in hemodialysis 
patients and found that the serum total LDH activity was not significantly different compared 
with the NEPHR group (308±7 U/l, p=0.703)and did not differ from the NON-NEPHR and 
CONTR groups.  
Serum total LDH activity correlated negatively with e serum total protein and serum 
albumin level (r= -0.549 p<0.001; r=-0.596 p<0.001) and positively with proteinuria and 
serum total cholesterol level (r=0.456 p<0.001; r=0.523, p<0.001). 
Serum LDH-2 activity was found to correlate negatively with the serum total protein and 
serum albumin level and positively with proteinuria and serum total cholesterol level. We 
analyzed the correlations with the ratio of serum LDH-2 as well, and we found that it also 
correlated negatively with serum total protein and serum albumin level (r= -0.607, p<0.001; 
r= -0.482, p<0.001), and positively with proteinuria and serum total cholesterol level 
(r=0.658, p<0.001; r=0.648, p<0.001). 
As a result of the linear regression analysis, serum total protein level proved to be 
independent predictor of serum total LDH activity (B=-5.831 β=-0.648 p<0.001) while serum 
total protein and proteinuria were verified as predictors of LDH-2 (B=-0.273 β=-0.457 
p=0.007; B=1.121, β=0.428, p=0.011).  
During a 300 weeks follow-up period, renal survival curves of nephrotic syndrome patients 
did not differ significantly between patients with LDH above and below the median LDH 
value (p=0.196). 
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We conclude, that LDH is an activity marker in nephrotic syndrome and together with 
isoezyme analysis might give important information about the activity and severity of the 
disease.
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Table A. Body mass index, fasting plasma glucose, lipid profile and carotid intima-media thickness in subjects withmetabolic syndrome, type 
2diabetes mellitus and controls by individual genotypes 
G
C
K
R
 (
rs
78
00
94
) 
 Control  T2DM  MS 
GG 
n=44 
GA 
n=93 
AA  
n=35 
GG 
n=77 
GA 
n=151 
AA  
N=78 
GG 
n=121 
GA 
n=217 
AA  
n=100 
BMI (kg/m2) 
23.6 
 (21.2-28.6) 
23.9 
 (15.8-32.8) 
23.8 
 (13.7-26.8) 
29.2 
(17.0-48.6) 
29.0 
(18.3-45.9) 
27.3 
(18.3-43.4) 
32.5 
(22.5-52.5) 
32.7 
(20.4-48.1) 
32.9 
(19.4-60.5) 
Fasting plasma glucose 
(mmol/l) 
N/A N/A N/A 
9.50 
(3.00-17.0) 
9.20 
(3.80-22.8) 
8.90 
(2.30-17.1)* 
9.60 
(3.80-19.1) 
8.80 
(3.00-30.8) 
8.50 
(4.51-16.6)* 
Serum triglycerides 
(mmol/l) 
1.35 
 (0.50-2.90) 
1.50 
 (0.80-3.60) 
1.70 
(0.70-3.20)* 
1.77 
(0.38-8.23) 
1.81 
(0.35-6.22) 
2.24 
(0.66-14.8)* 
2.07 
(0.49-7.76) 
2.68 
(0.35-14.2)* 
3.07 
(0.78-12.3)# 
Serum total-
cholesterol (mmol/l) 
5.48±0.80 5.44±0.94 5.04±1.04 5.01±1.02 4.60±1.12 4.75±1.10 5.03±1.05 5.15±1.36 5.35±1.26 
Serum HDL-
cholesterol (mmol/l) 
N/A N/A N/A 
1.39 
(0.76-2.48) 
1.25 
(0.68-2.37) 
1.19 
(0.62-2.49)* 
1.21 
(0.77-1.99) 
1.22 
(0.55-2.12) 
1.17 
(0.79-1.88) 
Serum LDL-
cholesterol (mmol/l) 
N/A N/A N/A 2.84±0.90 2.64±0.83 2.75±0.89 2.08±0.81 2.70±0.83 3.06±0.92* 
CIMT (mm) N/A N/A N/A 0.81±0.42 0.86±0.38 0.95±0.44 0.79±0.28 0.87±0.32 1.06±0.26* 
* p < 0.05 vs. GG; # p < 0.001 vs. GG; BMI, body mass index; CIMT, carotid intima-media thickness; HDL, high-density lipoprotein;LDL, low-
density lipoprotein; MS, metabolic syndrome; T2DM, type 2 diabetes mellitus; Data are mean ± SD or median (minimum-maximum) as 
appropriate 
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Table B. Body mass index, fasting plasma glucose, lipid profile and carotid intima-media thickness in subjects withmetabolic syndrome, type 
2diabetes mellitus and controls by individual genotypes 
 
G
C
K
R
 (
rs
12
60
32
6) 
 Control  T2DM  MS 
CC 
n=48 
TC 
n=80 
TT 
n=44 
CC 
n=80 
TC 
n=155 
TT 
n=63 
CC 
n=118 
TC 
n=219 
TT 
n=91 
BMI (kg/m2) 
23.7 
(20.8-28.6) 
23.8 
(15.8-32.8) 
23.8 
(13.7-26.8) 
29.2 
(17.0-37.6) 
29.3 
(18.3-45.9) 
28.9 
(18.3-38.6) 
31.8 
(20.4-49.57) 
32.8 
(19.4-52.5) 
33.4 
(25.0-60.5) 
Fasting plasma glucose 
(mmol/l) 
N/A N/A N/A 
9.05 
(3.00-16.9) 
8.90 
(2.30-17.1) 
8.70 
(2.30-22.8)* 
9.80 
(3.20-20.0) 
8.60 
(3.90-30.8) 
8.40 
(3.00-16.6)* 
Serum triglycerides 
(mmol/l) 
1.51 
(0.50-2.90) 
1.55 
(0.70-2.90) 
1.68 
(0.80-3.60)* 
1.45 
(0.35-4.28) 
1.87 
(0.39-8.23)* 
2.32 
(0.59-14.9)* 
2.19 
(0.70-7.86) 
2.72 
(0.35-14.4)* 
2.91 
(0.78-11.5)* 
Serum total-cholesterol 
(mmol/l) 
5.44±0.87 5.41±0.96 5.20±0.99 5.03±1.11 4.64±0.97 4.72±1.32 5.10±1.02 5.21±1.38 5.20±1.27 
Serum HDL-cholesterol 
(mmol/l) 
N/A N/A N/A 
1.39 
(0.76-2.48) 
1.27 
(0.68-2.47) 
1.17 
(0.62-2.49)* 
1.23 
(0.70-1.96) 
1.16 
(0.55-2.12) 
1.23 
(0.79-1.88) 
Serum LDL-cholesterol 
(mmol/l) 
N/A N/A N/A 2.85±0.88 2.63±0.78 2.78±1.05 2.71±0.81 2.85±0.82 3.00±0.93* 
CIMT (mm) N/A N/A N/A 0.81±0.41 0.88±0.43 0.95±0.44 0.83±0.30 0.87±0.38 1.05±0.28* 
* p<0.05 vs. CC; BMI, body mass index; CIMT, carotid intima-media thickness; HDL, high-density lipoprotein;LDL, low-density lipoprotein; 
MS, metabolic syndrome; T2DM, type 2 diabetes mellitus; Data are mean ± SD or median (minimum-maximum) as appropriate 
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5. THESES 
 
1. G900C polymorphism of FN3K gene is associated with the HbA1c level, with 
the duration of T2DM and with the age at onset of T2DM, but not with the 
diabetic microvascular complications. 
 
2. In T2DM, functional variants of the GCKR gene (rs780094, rs1260326) are 
associated with serum triglycerides, with the fasting plasma glucose level, with 
the HDL-cholesterol level and CIMT. In metabolikuc syndrome,both 
functional variants are associated with serum triglycerides, with the fasting 
plasma glucose level, with the LDL-cholesterol leve and CIMT. None of the 
variants are associated with the diabetic microvascul r complications. 
 
3. Serum LDH and LDH-2 isoenzyme correlates with routine laboratory 
parameters of nephrotic syndrome. Serum LDH and LDH-2 isoenzyme is an 
activity marker, but not a prognostic marker of nephrotic syndrome. 
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